HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peptides partnership

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic ingredient manufacturer Degussa Goldschmidt and biotech firm Helix BioMedix have signed an agreement naming Goldschmidt the exclusive marketing partner for BioMedix's Combikine and Replikine anti-aging peptides along with other selected peptides for skin-care applications, the firms announce Sept. 5. "Accessing Helix BioMedix's portfolio of innovative peptides and combining it with our extensive formulation know-how and claims validation capabilities substantially supports our competitive advantage in creating the next generation of safe and effective personal care products," states Mike Farwick, head of active ingredients R&D for Goldschmidt, Personal Care. BioMedix designs, synthesizes and characterizes bioactive peptides for cosmeceutical, acne treatment, anti-infection and wound-healing applications. In addition to supplying raw cosmetic materials, Degussa parent company Goldschmidt GmbH manufactures human skin identical sphingolipids such as ceramides...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS014961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel